search
Back to results

Transcutaneous Electrical Stimulation in Obstructive Sleep Apnea

Primary Purpose

Obstructive Sleep Apnea

Status
Completed
Phase
Not Applicable
Locations
Belgium
Study Type
Interventional
Intervention
Transcutaneous electrical stimulation
Sponsored by
Sunrise
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Obstructive Sleep Apnea

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria:

  • Obstructive apnea-hypopnea index > 15 events/hour
  • Patients who do not tolerate or do not accept positive airway pressure therapy

Main exclusion criteria:

  • Body mass index < 18.5 or > 32 kg/m2
  • Unable or incapable of providing informed written consent
  • Unwilling or incapable of returning to all follow-up visits and sleep studies, including evaluation procedures and filling out questionnaires
  • Significant co-morbidities making the patient unable or inappropriate to participate in the trial

Sites / Locations

  • Respisom

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Transcutaneous electrical stimulation

Arm Description

Participants will be asked to use the stimulator for 6 weeks at home. The study objectives will be evaluated after 6 weeks post-activation of the device.

Outcomes

Primary Outcome Measures

Apnea-hypopnea index (AHI)
Change from baseline to 6 weeks in the apnea-hypopnea index (AHI)

Secondary Outcome Measures

Full Information

First Posted
June 3, 2021
Last Updated
April 13, 2023
Sponsor
Sunrise
search

1. Study Identification

Unique Protocol Identification Number
NCT04932486
Brief Title
Transcutaneous Electrical Stimulation in Obstructive Sleep Apnea
Official Title
Randomised Controlled Trial of Transcutaneous Electrical Stimulation in Obstructive Sleep Apnea
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Completed
Study Start Date
May 26, 2021 (Actual)
Primary Completion Date
April 13, 2023 (Actual)
Study Completion Date
April 13, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sunrise

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
The aim of this study is to assess the efficacy of transcutaneous electrical stimulation of the upper airway muscles in patients with obstructive sleep apnea.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obstructive Sleep Apnea

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
42 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Transcutaneous electrical stimulation
Arm Type
Experimental
Arm Description
Participants will be asked to use the stimulator for 6 weeks at home. The study objectives will be evaluated after 6 weeks post-activation of the device.
Intervention Type
Device
Intervention Name(s)
Transcutaneous electrical stimulation
Intervention Description
Transcutaneous electrical stimulation of the upper airway muscles
Primary Outcome Measure Information:
Title
Apnea-hypopnea index (AHI)
Description
Change from baseline to 6 weeks in the apnea-hypopnea index (AHI)
Time Frame
6 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria: Obstructive apnea-hypopnea index > 15 events/hour Patients who do not tolerate or do not accept positive airway pressure therapy Main exclusion criteria: Body mass index < 18.5 or > 32 kg/m2 Unable or incapable of providing informed written consent Unwilling or incapable of returning to all follow-up visits and sleep studies, including evaluation procedures and filling out questionnaires Significant co-morbidities making the patient unable or inappropriate to participate in the trial
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jean-Benoit Martinot
Organizational Affiliation
Respisom
Official's Role
Principal Investigator
Facility Information:
Facility Name
Respisom
City
Namur
ZIP/Postal Code
5000
Country
Belgium

12. IPD Sharing Statement

Learn more about this trial

Transcutaneous Electrical Stimulation in Obstructive Sleep Apnea

We'll reach out to this number within 24 hrs